Calamos Advisors LLC Boosts Position in Bristol-Myers Squibb Company (BMY)
Calamos Advisors LLC boosted its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 3.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 308,825 shares of the biopharmaceutical company’s stock after purchasing an additional 10,369 shares during the period. Calamos Advisors LLC’s holdings in Bristol-Myers Squibb were worth $17,208,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of BMY. First Trust Advisors LP boosted its position in Bristol-Myers Squibb by 10.7% in the 2nd quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock valued at $24,130,000 after buying an additional 41,892 shares during the period. Toronto Dominion Bank boosted its position in Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after buying an additional 162,884 shares during the period. Mutual of America Capital Management LLC boosted its position in Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after buying an additional 3,833 shares during the period. Dividend Assets Capital LLC purchased a new position in Bristol-Myers Squibb in the 2nd quarter valued at approximately $737,000. Finally, Quantitative Investment Management LLC purchased a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $6,150,000. Hedge funds and other institutional investors own 68.97% of the company’s stock.
Shares of Bristol-Myers Squibb Company (BMY) opened at $61.14 on Friday. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market cap of $100,067.84, a price-to-earnings ratio of 20.66, a P/E/G ratio of 2.41 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. Bristol-Myers Squibb’s revenue was up 6.7% compared to the same quarter last year. analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.
Several brokerages have commented on BMY. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target for the company. in a research report on Thursday, September 28th. Finally, Cowen Inc set a $65.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.93.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.23% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/24/calamos-advisors-llc-boosts-position-in-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.